A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1035-1040

  Vermorken, J B ^a   Kobierska, A ^b   Chevallier, B ^c   Zanaboni, F ^d   Pawinski, A ^e   Bolis, G ^e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c CENTRE HENRI BECQUEREL   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e EORTC DATA CENTER   (Belgium)

Author keywords

High dose epirubicin; Ovarian cancer; Phase II

Indexed keywords

CISPLATIN; EPIRUBICIN;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0033806775     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008332517333     Document Type: Article

References (29)

1. Chemotherapy of advanced ovarian cancer
2. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
3. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial
4. The development of new cytotoxic drugs for ovarian cancer: Review of the literature and methodological aspects
5. Cyclophosphamide plus cisplatin vs cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
6. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide vs. cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
7. Impact of doxorubicin on survival in advanced ovarian cancer
8. Meta-analysis of chemotherapy regimens for ovarian carcinoma: A reassessment of cisplatin, cyclophosphamide and doxorubicin vs. cisplatin and cyclophosphamide
9. Second trial drugs in ovarian cancer
10. Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy
11. Adriamycin in ovarian cancer patients resistant to cyclophosphamide
12. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients
13. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modificstions by liposomal encapsulation
14. Phase II study of high-dose epirubicin (HDE) in ovarian cancer patients previously treated with cisplatin
15. Antitumor activity of high-dose epirubicin in patients with ovarian cancer failing platinum-based regimens
16. Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma
17. Treatment of recurrent ovarian cancer: Increasing options - 'Recurrent' results
18. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariaye analysis of 704 patients
19. Topotecan vs. paclitaxel for the treatment of recurrent epithelial ovarian cancer
20. Trattamento di 2 linea del carcinoma ovarico avanzato con epirubicina
21. Epirubicin for pretreated advanced ovarian cancer
22. Phase II trial of epirubicin at standard dose in relapsed ovarian cancer
23. A phase II study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer
24. Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings
25. Inhibition of human ovarian cancer colony formation by adriamycin and its metabolites
26. Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches
27. The taxoids. Comparative clinical pharmacology and therapeutic potential
28. The role of anthracyclines in epithelial ovarian cancer